Amitriptyline is NOT recommended for anxiety disorders
Amitriptyline should not be used as a treatment for anxiety disorders, as it is not supported by current guidelines and superior alternatives exist. While the FDA label indicates amitriptyline is approved for depression (not anxiety) 1, and older research from the 1970s showed some benefit for anxiety symptoms 2, 3, modern evidence-based guidelines do not recommend tricyclic antidepressants like amitriptyline as first-line or even second-line treatment for anxiety disorders.
Why Amitriptyline Should Be Avoided for Anxiety
Guideline Recommendations Explicitly Advise Against It
The most recent and authoritative guidelines consistently exclude amitriptyline from recommended treatments:
The 2023 Japanese Society guidelines for social anxiety disorder list SSRIs (escitalopram, sertraline, fluvoxamine, paroxetine) and SNRIs (venlafaxine) as standard pharmacotherapy, with no mention of tricyclic antidepressants 4
The Canadian Clinical Practice Guideline specifically deprecates tricyclic antidepressants (listing imipramine as not recommended based on negative evidence) 4
The 2002 World Federation of Societies of Biological Psychiatry guidelines state that while TCAs are "equally effective" to SSRIs for panic disorder, "they are less well tolerated than the SSRIs" 5
Evidence Shows Inferior Tolerability
Even when amitriptyline demonstrated some efficacy in older studies, it showed problematic side effects:
A 1977 comparative trial found that amitriptyline caused significantly more drowsiness and dry mouth compared to alternatives, with the sedative properties failing to adequately substitute for specific anxiolytic effects 6
The FDA label itself notes amitriptyline requires careful dose titration and monitoring, with doses ranging from 75-300 mg daily for depression 1 - these higher doses would likely be poorly tolerated in anxiety patients who are often sensitive to medication side effects
What Should Be Used Instead
First-Line Treatment: SSRIs and SNRIs
For any anxiety disorder, initiate treatment with an SSRI (escitalopram or sertraline preferred) or SNRI (venlafaxine) 4, 7, 8:
- Start at low doses and titrate gradually
- Allow 4-6 weeks for full therapeutic effect
- Continue for 6-12 months after remission 7
Second-Line Options
If SSRIs/SNRIs fail or are not tolerated:
- Pregabalin for generalized anxiety disorder
- Moclobemide (where available) for social anxiety
- Short-term benzodiazepines only for acute symptom relief while awaiting SSRI effect, not for routine long-term use 5, 8
Combine with Cognitive Behavioral Therapy
CBT should be offered alongside or instead of medication - it has the highest level of evidence for anxiety disorders and provides durable benefits 4, 8
The Only Potential Exception
The 2022 Cochrane review on PTSD found low-certainty evidence that amitriptyline improved PTSD symptoms (50% response vs 17% placebo) 9. However, even for PTSD, SSRIs remain first-line treatment with moderate-certainty evidence, making amitriptyline at best a distant alternative when multiple other options have failed.
Clinical Bottom Line
There is no clinical scenario where amitriptyline should be a first, second, or even third choice for anxiety disorders in 2024. The combination of limited efficacy evidence, poor tolerability, and availability of superior alternatives makes its use for anxiety unjustifiable in modern practice.